CD276 and cancer: While genetic disruption of the CD276 gene using CRISPR-Cas9 rendered sensitive cancer cell types >100-fold resistant to the m276-SL-PBD, highlighting the necessity of the target for potent killing, intrinsic factors appeared to render other cancer types relatively resistant to ADC killing even when CD276 target was present at high levels.